Duke Comp Cancer Inst. Core Support Grant

杜克大学癌症研究所

• 批准号: 8324995
• 负责人: Michael B Kastan
• 金额: $ 572.38万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8324995
• 关键词: Advisory Committees; American Cancer Society; Area; Arts; Basic Science; Biology; Biomedical Research; Brain Neoplasms; Breast; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Patient; Cells; Chairperson; Charge; Chemicals; Clinical; Clinical Oncology; Clinical Research; Collaborations; Comprehensive Cancer Center; Data; Department of Defense; Detection; Development; Developmental Biology; Discipline of Nursing; Doctor of Medicine; Doctor of Philosophy; Duke Comprehensive Cancer Center; Engineering; Enrollment; Funding; Future; Genomics; Gifts; Goals; Grant; Hematologic Neoplasms; Institutes; Instruction; Interdisciplinary Study; Journals; Laboratories; Leadership; Malignant Neoplasms; Medicine; Molecular; Names; National Cancer Institute; Nucleic Acids; Outpatients; Ovarian; Paper; Patients; Peer Review; Pharmacology; Pilot Projects; Population Research; PubMed; Publications; Publishing; Radiation Oncology; Recruitment Activity; Regulation; Reporting; Request for Applications; Research; Research Activity; Research Institute; Resource Sharing; Resources; Schools; Science; Scientific Advances and Accomplishments; Scientist; Signal Pathway; Signal Transduction; Societies; Source; Testing; Therapeutic; Therapeutic Clinical Trial; Translational Research; Universities; University Hospitals; anticancer research; authority; cancer care; cancer genetics; cancer genomics; cancer prevention; cancer risk; chemotherapy; empowered; hematopoietic cell transplantation; improved; innovation; insight; interest; medical schools; meetings; member; neuro-oncology; oncology; operation; programs; statistical center; structural biology

PROJECT SUMMARY (See instructions): Duke Comprehensive Cancer Institute Herbert K.Lyerly, M.D., Director The recently reorganized Duke Comprehensive Cancer Institute (DCCI) is charged to serve as the center of all Duke activities in cancer, with an imperative to oversee all of the Duke cancer operations in the future. As a matrix center in one of the largest biomedical research institutes, the DCCI has been continuously supported by the National Cancer Institute (NCI) for over 36 years, by leveraging Duke's basic research strengths with significant clinical oncology research excellence which is enabled by treating 5,581 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. Total membership in the DCCI is 285 members, with members having an increasingly prominent focus in cancer research and increased amount of NCI funding since 2004. Total funding for program members is $331,617,013, of which $269,525,804 is from peer-reviewed sources. A cancer focus is illustrated by $77,785,582 or 23.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004-2008, program members published 6,941 papers in peer-reviewed journals cited in PubMed. Of these publications, 10% are the result of intra-programmatic collaborations and 19% due to inter-programmatic collaborations. In this competitive renewal application, we request support our membership in 11 Research Programs supported by 17 Shared Resources. DCCI members made significant scientific advances including: the development of innovative genomic tests to predict which cancer patients would respond to specific chemotherapy, and basic insight into critical signaling pathways in cancer and developmental biology. The DCCI oversees all cancer related philanthropy at Duke, and these funds have been used to support recruitment of new members, innovative pilot projects, support of multidisciplinary research, and new laboratory and administrative space. This application for ongoing support of the DCC articulates the principles, goals and strategies for propelling the DCCI to fully leverage the enormous advances in biomedical research at Duke and beyond, to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.

项目总结（见说明）： 杜克综合癌症研究所 赫伯特K.莱尔利，医学博士，主任 最近重组的杜克综合癌症研究所（DCCI）负责作为所有杜克癌症活动的中心，有必要监督所有的杜克癌症手术在未来。作为最大的生物医学研究机构之一的矩阵中心，DCCI通过利用杜克的基础研究，36年来一直得到国家癌症研究所（NCI）的支持 该研究所拥有显著的临床肿瘤学研究优势，每年治疗5，581名新癌症患者，每年招募1，000多名患者进行治疗性临床试验，并通过国家肿瘤学研究资源的存在得到加强，例如两个NCI资助的合作团体的数据和统计中心。DCCI的成员总数为285名，其中成员拥有 自2004年以来，癌症研究的重点日益突出，NCI的资助金额也有所增加。计划成员的资金总额为331，617，013美元，其中269，525，804美元来自同行评审来源。癌症焦点由来自NCI、美国癌症协会或美国癌症协会的77，785，582美元或23.5%的资金来说明。 国防部从2004年到2008年，项目成员在PubMed引用的同行评审期刊上发表了6，941篇论文。在这些出版物中，10%是计划内合作的结果，19%是计划间合作的结果。在此竞争性续约申请中，我们请求支持 我们在11个研究项目中的成员资格，由17个共享资源支持。DCCI成员取得了重大的科学进展，包括：开发创新的基因组测试来预测哪些癌症患者会对特定的化疗产生反应，以及对癌症和发育生物学中关键信号通路的基本见解。DCCI负责监督杜克大学所有与癌症相关的慈善事业以及这些基金 已被用于支持招募新成员，创新试点项目，支持多学科研究，以及新的实验室和行政空间。本申请书旨在为DCC提供持续支持，阐明了推动DCCI充分利用杜克及其他地区生物医学研究的巨大进步，以改善和延长癌症生命的原则、目标和策略 癌症患者和有癌症风险的患者，并将这些患者提供给社会。